Financial update from BioHarvest Sciences for the second quarter of 2025
BioHarvest Sciences Inc. Announces Growth Strategy and Initiatives for Second Half of 2025
BioHarvest Sciences Inc., a leading company in Botanical Synthesis, has unveiled its growth strategy and upcoming initiatives for the second half of 2025. The strategy focuses on three major areas: launching the Health Pros Professional Affiliate Program, entering the hydration and sports drink market, and expanding their Contract Development and Manufacturing Organization (CDMO) services.
The Health Pros Professional Affiliate Program, set to launch in September 2025, aims to enroll 300 health professionals by the end of the year. This program is part of BioHarvest's ongoing efforts to increase its presence in the health and wellness sector.
In October 2025, BioHarvest plans to enter the hydration and sports drink market with the launch of "Blood Flo® Hydration Solution." This move is expected to diversify the company's product portfolio and cater to the needs of athletes and individuals with active lifestyles.
The company's CDMO services are also set for expansion. BioHarvest has already announced the first CDMO project to reach Stage 2, with the completion of Stage 1 development for a CDMO contract with a Nasdaq-listed pharmaceutical company. Additionally, BioHarvest has secured a new Stage 1 CDMO contract to develop a plant-based fragrance compound. Further CDMO projects are expected to progress in the second half of 2025.
These initiatives accompany ongoing strong performance from BioHarvest's VINIA® capsule business, which continues to drive the majority of growth. In Q2 2025, the company reported a 41% year-over-year revenue increase to $8.5 million, with the core capsule business growing by 28% and new products increasing by 100%.
Management expects Q3 2025 revenues of at least $9.1 million and is optimistic about reaching adjusted EBITDA breakeven in Q4 2025. The CDMO pipeline remains robust, with multiple potential customers expected to convert within 6–9 months.
BioHarvest Sciences operates in two major business verticals: as a CDMO on behalf of customers seeking novel plant-based compounds, and as a creator of proprietary nutraceutical health and wellness products. The company's stock is traded on NASDAQ under the symbol BHST and on the Frankfurt Stock Exchange under the symbol 8MV0.
For more information, investors can access the telephone playback of the Q2 2025 earnings call until Monday, August 25, 2025. To access it, dial 1-844-512-2921 within the US and Canada, or 1-412-317-6671 internationally, using replay pin number 10199237. A webcast replay will also be available at the provided webcast link.
For investor relations inquiries, please contact Dave Ryan, VP Investor Relations, at (604) 622-1186 or [email protected]. For MZ Group inquiries, contact Lucas A. Zimmerman at (949) 259-4987 or [email protected].
[1] BioHarvest Sciences Inc. Press Release, Q2 2025 Financial Results, August 10, 2025. [2] BioHarvest Sciences Inc. Investor Presentation, Q2 2025, August 10, 2025. [3] BioHarvest Sciences Inc. Consolidated Statements of Cash Flows, Q2 2025, August 10, 2025. [4] BioHarvest Sciences Inc. Non-IFRS Measure Adjusted EBITDA, Q2 2025, August 10, 2025. [5] BioHarvest Sciences Inc. Form 6-K, Q2 2025, August 10, 2025.
Investors may find interest in BioHarvest Sciences Inc.'s upcoming business initiatives, such as the launch of the Health Pros Professional Affiliate Program focused on health and wellness, the entry into the hydration and sports drink market with "Blood Flo® Hydration Solution," and the expansion of their Contract Development and Manufacturing Organization (CDMO) services. These initiatives are part of the company's growth strategy announced for the second half of 2025, as they seek to diversify their product offerings and cater to various markets, including finance and real-estate, through their business ventures and partnerships.
